Stoxline.com

Stock Symbol:   

Stoxline Mobile
Home  |  Stock Charts  |  Showcases  |  Stock Ranks  |  Options  |  ETFs  |  Educations

Psychemedics Corporation (PMD)

9.35   -0.06 (-0.64%) 10-17 16:00
Open: 9.5 Pre. Close: 9.41
High: 9.5 Low: 9.25
Volume: 8,266 Market Cap: 52M
Psychemedics Corp provides testing services for the detection of drugs of abuse through the analysis of hair samples. This information is useful to employers for both applicant and employee testing, as well as to physicians and among others.

Stock Price Prediction

Update at 5:00pm EST
If tomorrow: Open lower Open higher
High: 9.505 - 9.554 9.554 - 9.591
Low: 9.137 - 9.188 9.188 - 9.227
Close: 9.27 - 9.355 9.355 - 9.42

Technical analysis

as of: 2019-10-17 4:28:47 PM
Overall:       
Stoxline posted a NEUTRAL today, downgraded from higher rating. Current trend continues, but could change at anytime. It is not a good time to buy or sell.
Target: Six months: 11.27     One year: 13.16
Support: Support1: 8.84    Support2: 8.34
Resistance: Resistance1: 9.65    Resistance2: 11.27
Pivot: 9.19
Moving Average: MA(5): 9.31     MA(20): 9.18
MA(100): 8.95     MA(250): 13.01
MACD: MACD(12,26): 0.23     Signal(9): 0.24
Stochastic oscillator: %K(14,3): 92.85     %D(3): 83.27
RSI: RSI(14): 59.04
52-week: High: 19.64  Low: 7.12  Change(%): -49.2
Average Vol(K): 3-Month: 2216  10-Days: 1193

Price, moving averages and Bollinger Bands

Price and moving averages has closed above its Short term moving average. Short term moving average is currently above mid-term; AND above long term moving averages. From the relationship between price and moving averages; we can see that: This stock is BULLISH in short-term; and NEUTRAL in mid-long term.
PMD has closed below upper band by 24.0%. Bollinger Bands are 53% narrower than normal. The narrow width of the bands suggests low volatility as compared to PMD's normal range. The bands have been in this narrow range for 6 bars. This is a sign that the market may be about to initiate a new trend.

Headline News

2019-08-08
The Daily Biotech Pulse: Glaukos To Buy Avedro, Mixed Adcom Vote For Gilead, Dynavax Offering
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks hitting 52-week highs on Aug. 7) Akero Therapeutics Inc (NASDAQ: AKRO ) Allakos Inc (NASDAQ: ALLK ) Cytokinetics, Inc. (NASDAQ: CYTK ) Guardant Health Inc (NASDAQ: GH ) (reacted to strong second-quarter results) Morphic Holding Inc (NASDAQ: MORF ) West Pharmaceutical Services Inc. (NYSE: WST ) Down In The Dumps (Biotech stocks hitting 52-week lows on Aug. 7) ABIOMED, Inc. (NASDAQ: ABMD ) Assertio Therapeutics Inc (NASDAQ: ASRT ) Bellicum Pharmaceuticals Inc (NASDAQ: BLCM ) Bicycle Therapeutics PLC (NASDAQ: BCYC ) BioCardia Inc (NASDAQ: BCDA ) BIOLINERX LTD/S ADR (NASDAQ: BLRX ) Biopharmx Corp NYSE: (BPMX) CAN-FITE BIOPHA/S ADR (NYSE: CANF ) CELLECT BIOTECH/S ADR (NASDAQ: APOP ) Cellular Biomedicine Group Inc (NASDAQ: CBMG )(reacted to second-quarter results) Eloxx Pharmaceuticals Inc (NASDAQ: ELOX )(reported second-quarter results) Guardion Health Sciences Inc (NASDAQ: GHSI )(announced common stock offering of 9.

2019-08-06
The Daily Biotech Pulse: Sanofi's Dupixent Found Effective For Pediatric Itchy Skin, Novavax Gets Nod For Late-Stage Study, Allakos Offering
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks No biotech stocks hit 52-week highs Monday. Down In The Dumps (Biotech stocks hitting 52-week lows on Aug. 5) Acer Therapeutics Inc (NASDAQ: ACER ) Aclaris Therapeutics Inc (NASDAQ: ACRS ) Actinium Pharmaceuticals Inc (NYSE: ATNM ) Adaptimmune Therapeutics PLC – ADR (NASDAQ: ADAP ) Adaptive Biotechnologies Corp (NASDAQ: ADPT ) Agios Pharmaceuticals Inc (NASDAQ: AGIO ) Akcea Therapeutics Inc (NASDAQ: AKCA )(announced its subsidiary Keryx Biopharmaceuticals has reached a settlement agreement with Endo International PLC (NASDAQ: ENDP )'s Par Pharam related to Auryxia) Akebia Therapeutics Inc (NASDAQ: AKBA ) Alder Biopharmaceuticals Inc (NASDAQ: ALDR ) Amneal Pharmaceuticals Inc (NYSE: AMRX )( reported below-consensus Q2 results and cut its 2019 guidance) AnaptysBio Inc (NASDAQ: ANAB ) Arcus Biosciences Inc (NYSE: RCUS ) Assertio Therapeutics Inc (NASDAQ: ASRT ) Atara Biotherapeutics Inc (NASDAQ: ATRA ) Bellicum Pharmaceuticals Inc (NASDAQ: BLCM ) Atreca Inc (NASDAQ: BCEL ) Cellectis SA (NASDAQ: CLLS ) Champions Oncology Inc (NASDAQ: CSBR ) China SXT Pharmaceuticals Inc (NASDAQ: SXTC ) Crinetics Pharmaceuticals Inc (NASDAQ: CRNX ) Cyclerion Therapeutics Inc (NASDAQ: CYCN ) Eloxx Pharmaceuticals Inc (NASDAQ: ELOX )(commenced Phase 2 study of ELX-02 in cystinosis) Endo International Enochian Biosciences Inc (NASDAQ: ENOB ) ESSA Pharma Inc (NASDAQ: EPIX ) Galmed Pharmaceuticals Ltd (NASDAQ: GLMD )(reacted to Q2 results) GENFIT S A/ADR (NASDAQ: GNFT ) GlycoMimetics Inc (NASDAQ: GLYC )(reported that Phase 3 trial evaluating sickle cell disease drug it is co-developing with Pfizer Inc.

Financial Analysis

Growth
Growth measures the growth of both a company's revenue and net income. it tells investors how fast a company is growing.
Profitability
Profitability measures a company’s ability to generate earnings as compared to its expenses and other relevant costs.
Solvency
Solvency measures a company's ability to meet its long-term debts. Acceptable solvency ratios will vary from industry to industry.
Efficiency
Efficiency measures the strength of a company's return on invested capital. It can identify business that are better managed or not.
Click here to get more fundamental analysis.
Tweet this page Share on Facebook
Free Technical Analysis Charts

Stock Basics & Statistics

Exchange:  NASDAQ Capital Market
Sector:  Healthcare
Industry:  Diagnostics Research
Shares Out. (M) 5.52
Shares Float (M) 4.67
% Held by Insiders 7.85
% Held by Institutions 58.54
Shares Short (K) 17
Shares Short P. Month (K)

Stock Financials

EPS 0.640
Book Value (p.s.) 3.350
PEG Ratio
Profit Margin 8.86
Operating Margin 14.77
Return on Assets (ttm) 14.4
Return on Equity (ttm) 19.3
Qtrly Rev. Growth -13.9
Gross Profit (p.s.) 3.736
Sales Per Share
EBITDA (p.s.) 1.527
Qtrly Earnings Growth -34.70
Operating Cash Flow (M) 6.02
Levered Free Cash Flow (M) 5.28

Stock Valuations

P/E 14.61
P/E Growth Ratio -0.01
P/BV 2.79
P/S 7099313.00
P/CF 8.57

Dividends & Splits

Dividend 0.720
Dividend Yield 0.08
Dividend Pay Date 2019-08-16
Ex-Dividend Date 2019-08-05
Forward Dividend 0.720
Last Split Date
Last Split Ratio -1e+010
7 Binary Options
Your Ad Here
android_stock_chart
Stock Chart
stoxline_lite
Stoxline Lite
stoxline_pro
Stoxline Pro
Option_Calculator
Option Calculator
(c) 2006-2019 Stoxline.com | Contact us           
Data and information is provided for informational purposes only, and is not intended for trading purposes. Neither Stoxline.com nor its data provider shall be liable for any errors or delays in the content, or for any actions taken in reliance thereon. By accessing the Stoxline.com web site, a user agrees not to redistribute the information found therein.